Company / EPS (Diluted)
Fulcrum Therapeutics, Inc. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.18
FY2025
5-year range
-$2.44 / -$0.16
FY2021-FY2025
Trend
-637.5%
vs FY2024
Sector context
#99 of 204
Health Care
What the data says
EPS (Diluted) changed -638% YoY in FY2025, a notable deviation from the 4-year average annual change of -130%.
Based on SEC 10-K filings.
-1.18 in FY2025.
Improved from $-1.59 to $-1.18 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#99 of 204 in Health CareTop 49% of 204This company -$1.18 Sector average -$0.89
▼
-33.1% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 637.5% year-over-year.
- Ranks #99 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.18 | -637.5% |
| FY2024 | -$0.16 | +89.9% |
| FY2023 | -$1.59 | +34.8% |
| FY2022 | -$2.44 | -6.6% |
| FY2021 | -$2.29 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026